Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Atossa Genetics Inc (ATOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,156
  • Shares Outstanding, K 31,820
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,370 K
  • 36-Month Beta 3.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.98
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.26
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/15/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.32 +88.13%
on 01/25/18
0.89 -32.36%
on 02/01/18
+0.27 (+82.42%)
since 01/23/18
3-Month
0.22 +173.64%
on 12/20/17
0.89 -32.36%
on 02/01/18
+0.24 (+67.22%)
since 11/22/17
52-Week
0.22 +173.64%
on 12/20/17
1.65 -63.52%
on 03/15/17
-0.88 (-59.32%)
since 02/23/17

Most Recent Stories

More News
Quotidian Technical Highlights on Selected Healthcare Stocks -- Atossa Genetics, Palatin Technologies, Adamis Pharma, and Perrigo

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ATOS, PTN, ADMP, and PRGO which can be accessed for free by signing up to www.wallstequities.com/registration....

ADMP : 3.35 (+31.37%)
ATOS : 0.60 (+11.48%)
PTN : 0.98 (unch)
PRGO : 88.25 (+1.36%)
Analysis: Positioning to Benefit within NRG Energy, Foot Locker, Campbell Soup, Atossa Genetics, Gentex, and Genworth Financial -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NRG Energy, Inc. (NYSE:NRG),...

GNW : 2.89 (+1.40%)
NRG : 26.42 (+4.59%)
CPB : 44.12 (+0.36%)
FL : 48.25 (-0.02%)
ATOS : 0.60 (+11.48%)
GNTX : 23.47 (+1.12%)
Atossa Genetics to Present at Adoptive T-Cell Therapy Symposium - Molecular Medicine Tri-Conference on Thursday February 15, 2018

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it will...

ATOS : 0.60 (+11.48%)
Atossa Genetics Presents Additional Findings from its Phase 1 Study of Oral Endoxifen

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced additional...

ATOS : 0.60 (+11.48%)
"Dejà vu All Over Again?"

SAN FRANCISCO, CA / ACCESSWIRE / January 31, 2018 / Vista Partners ("Vista") has published January's FREE Macroeconomic & Investment Monthly Newsletter, "Dejà vu All Over Again?".

ATOS : 0.60 (+11.48%)
FSNN : 2.90 (+1.75%)
Atossa Genetics to Host Conference Call to Present Additional Findings from its Phase 1 Study of Oral Endoxifen Thursday February 1, 2018 at 4:30 pm EST

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today it will host...

ATOS : 0.60 (+11.48%)
"The Bright Lights of 2017"

SAN FRANCISCO, CA / ACCESSWIRE / December 29, 2017 / Vista Partners ("Vista") has published December's FREE Macroeconomic & Investment Monthly Newsletter, "The Bright Lights of 2017".

ATOS : 0.60 (+11.48%)
FSNN : 2.90 (+1.75%)
Atossa Genetics President and CEO Issues Letter to Stockholders Highlighting Key Accomplishments and Outlines Milestones for 2018

Atossa Genetics Inc. (NASDAQ:ATOS) today announced it has issued the following letter by Dr. Steven C. Quay, President and CEO, to Atossa stockholders:

ATOS : 0.60 (+11.48%)
Atossa Genetics Announces Pricing of $1.4 Million Registered Direct Offering

Atossa Genetics Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions,...

ATOS : 0.60 (+11.48%)
Blog Exposure - Neogen's Shareholders Set to Receive Additional Stock as the Company Announces Stock Split

Stock Monitor: Atossa Genetics Post Earnings Reporting

ATOS : 0.60 (+11.48%)
NEOG : 60.11 (+1.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting...

See More

Key Turning Points

2nd Resistance Point 0.65
1st Resistance Point 0.62
Last Price 0.60
1st Support Level 0.56
2nd Support Level 0.52

See More

52-Week High 1.65
Fibonacci 61.8% 1.10
Fibonacci 50% 0.94
Fibonacci 38.2% 0.77
Last Price 0.60
52-Week Low 0.22

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.